

NuProtect: Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A

Submission date 11/09/2013	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 22/10/2013	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 23/05/2022	Condition category Haematological Disorders	☐ Individual participant data

Plain English summary of protocol

Background and study aims

FVIII concentrates are the only available treatment for patients with severe haemophilia A. However, patients are at risk of developing resistance (inhibitor) to FVIII, which stops the treatment from working, and patients may also suffer from an allergic reaction. The drug under investigation, human-cl rhFVIII, is a newly developed recombinant FVIII concentrate from a human cell line, which may have less immunogenic potential (ability to provoke an immune response) compared to FVIII concentrates from hamster cell lines or plasma-derived FVIII concentrates. The main aim of the study is to investigate the immunogenicity of the new product in previously untreated patients with severe haemophilia A. This population is at the highest risk of developing inhibitors. Previous studies of the new product in already treated patients (adults and children) did not show a single case of inhibitor development.

Who can participate?

Previously untreated patients with severe haemophilia A.

What does the study involve?

All patients will receive the newly developed recombinant FVIII concentrate injection. The study involves regular blood sampling to screen for inhibitors. All patients adverse events are documented.

What are the possible benefits and risks of participating?

Human-cl rhFVIII may have less immunogenic potential compared to recombinant FVIII concentrates from hamster cell lines or plasma-derived FVIII concentrates. However, as for all FVIII concentrates, patients are at risk of developing an inhibitor to FVIII and may suffer from an allergic reaction.

Where is the study run from?

The study is planned to be conducted at about 45 study sites in 16 countries worldwide.

When is the study starting and how long is it expected to run for?
The study started in March 2013, and is planned to be completed in 2018.

Who is funding the study?
Octapharma AG, Switzerland

Who is the main contact?
Martina Jansen
Octapharma PPG
Clinical Research & Development Haematology
Oberlaaerstrasse 235
1100 Vienna, Austria

Contact information

Type(s)
Scientific

Contact name
Dr Raina Liesner

Contact details
Great Ormond Street Hospital for Children, NHS Trust
Haemophilia Centre
Great Ormond Street
London
United Kingdom
WC1N 3JH

Additional identifiers

Clinical Trials Information System (CTIS)
2012-002554-23

ClinicalTrials.gov (NCT)
NCT01712438

Protocol serial number
GENA-05

Study information

Scientific Title
Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A: a prospective, multinational, open-label, non-controlled study

Study objectives
Immunogenicity of Human-cl rhFVIII in previously untreated patients with severe haemophilia A is low.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Canada, HIREB Hamilton: 11 March 2013

Germany, Ethics Committee University Münster: 08 July 2013

Spain, Vall d'Hebron, Barcelona: 11 January 2013

France, CPP Ouest V, Nanterre: 07 February 2013

UK, NRES Committee London-Central: 19 February 2013

Georgia, Committee of Institute of Haematology, Tiflis: 17 January 2013

Moldova, National Ethics Committee, Chisinau: 29 January 2013

Poland, EC Medical University Warsaw: 12 February 2013

Russia, Izmailovskaya EC: 26 June 2013

Ukraine, National Academy of Medical Science: 04 February 2013

Study design

Prospective multicentre multinational open-label non-controlled study

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

Severe haemophilia A

Interventions

There is only one study arm. All patients receive the same investigational medicinal product (IMP) intravenously. The dose, frequency and duration are flexible, and depend on the individual clinical condition of the patient.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Human-cl rhFVIII

Primary outcome(s)

The immunogenic potential of the IMP. Each patient is tested for the development of inhibitors at treatment start, every three to four exposure days to the IMP, latterly every ten exposure days (latest every three months).

Key secondary outcome(s)

Safety, efficacy and tolerability: Efficacy (by assessing each treatment of a bleeding episode, or the rate of bleeds in case of prophylactic treatment) and safety (adverse events) are observed during the entire study duration, which is planned for a total of 100 exposure days with the IMP, but not longer than 5 years.

Completion date

24/03/2020

Eligibility

Key inclusion criteria

1. Male, no age limitations, but due to the required patient population it can be expected that the majority of patients going to be included are babies and small children.
2. Severe haemophilia A (FVIII:C < 1%)
3. No previous treatment with FVIII concentrates or other blood products containing FVIII
4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted (obtained from the patients parent/legal guardian)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex

Male

Key exclusion criteria

1. Diagnosis with a coagulation disorder other than haemophilia A
2. Severe liver or kidney disease (alanine amino transferase (ALT) or aspartate transaminase (AST) levels >5 times of upper limit of normal, creatinine >120 µmol/L)
3. Concomitant treatment with any systemic immunosuppressive drug
4. Participation in another interventional clinical study currently or during the past 4 weeks.

Date of first enrolment

01/03/2013

Date of final enrolment

30/06/2016

Locations

Countries of recruitment

United Kingdom

England

Brazil

Canada

Colombia

France

Georgia

Germany

India

Moldova

Morocco

Poland

Russian Federation

Spain

Ukraine

United States of America

Venezuela

Study participating centre

Great Ormond Street Hospital for Children, NHS Trust

London

United Kingdom

WC1N 3JH

Sponsor information

Organisation

Octapharma AG (Switzerland)

ROR

<https://ror.org/002k5fe57>

Funder(s)

Funder type

Industry

Funder Name

Octapharma AG (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results	EU Clinical Trials Register results	23/08/2020	20/05/2022	No	No
Basic results	ClinicalTrials.gov results	21/10/2019	23/05/2022	No	No
Interim results article	interim results	01/03/2018	14/05/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes